Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • Find a professional representative
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • Find a professional representative
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t950051eu1
  1. Home
  2. T 0051/95 (Mature leukocyte interferons/HOFFMANN-LA-ROCHE) 19-11-1998
Facebook Twitter Linkedin Email

T 0051/95 (Mature leukocyte interferons/HOFFMANN-LA-ROCHE) 19-11-1998

European Case Law Identifier
ECLI:EP:BA:1998:T005195.19981119
Date of decision
19 November 1998
Case number
T 0051/95
Petition for review of
-
Application number
86105365.0
IPC class
C12N 15/20
Language of proceedings
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN (C)

Download and more information:

Decision in EN 872.09 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Mature human leukocyte interferons, process for their bacterial production, intermediates therefor and compositions containing them

Applicant name
F. Hoffmann-La Roche AG, et al
Opponent name

Boehringer Ingelheim GmbH

Amgen Inc

Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 114(1) 1973
European Patent Convention Art 112(1) 1973
European Patent Convention Art 87 1973
European Patent Convention Art 88 1973
European Patent Convention Art 54 1973
European Patent Convention Art 56 1973
European Patent Convention R 88 1973
Keywords

Inventive step - yes

New ground for opposition

Catchword
-
Cited decisions
G 0003/89
G 0003/93
G 0009/91
T 0081/87
Citing decisions
-

I. European patent No. 0 211 148 with the title "Mature human leukozyte interferons, process for their bacterial production, intermediates therefor and compositions containing them" was granted with 46 claims, on the basis of European application No. 86 105 365.0 with the four priority dates of 1 July 1980, 8 September 1980, 10 November 1980 and 21 April 1981. The publication of the grant of a patent took place on 26 August 1992.

Granted claim 1 read as follows:

"1. A mature human bacterially produced leukocyte interferon characterized in that it consists of 165-166 amino acids and contains Cys-Asp-Leu or Cys-Asn-Leu in positions 1, 2 and 3 and such mature leukocyte interferon with at the N-terminus an additional methionine residue."

Dependent claims 2 to 5 specified the sequence of the claimed leukocyte interferons (LeIF) at defined positions in the molecule. Dependent claims 6 to 13 related to interferons characterized by specific amino-acid sequences. Dependent claims 14 and 15 further defined the claimed interferons by the method of their production. The groups of claims 16 to 20, 21 to 23, 24 to 30, 31 to 33, 37 to 39, 41 to 43 were addressed respectively to DNAs, expression vectors, plasmids and bacterial hosts carrying/expressing the claimed interferons DNAs/proteins and uses thereof; claims 34 to 36 and 40 related to pharmaceutical preparations and the use of the claimed interferons for treatment. Claims 44 to 46 were addressed to processes for preparing the interferons, bacteria and expression vectors producing them.

II. Two notices of opposition were filed requesting the revocation of the patent in suit under Article 100(a) EPC (lack of novelty and inventive step). Appellant II (Opponent 02) also submitted at a later stage arguments alleging insufficiency of disclosure (Article 100(b)).

III. The Opposition Division maintained the patent in suit in amended form on the basis of the auxiliary claim request filed at oral proceedings which was identical to the granted set of claims but for the deletion of claim 5 and the subsequent renumbering of claims 6 to 46. They declined to accept into the proceedings the submissions pursuant to Article 83 EPC by Appellant II, as they had been submitted after the expiry of the opposition period.

IV. Both Appellants I and II (Opponents 01 and 02) filed an appeal, paid the appeal fee and submitted written statements setting out the grounds of their appeals.

V. The Respondent (Patentee) submitted his answer to the grounds of appeal.

VI. A communication was sent according to Article 11(2) of the Rules of Procedure of the Boards of Appeal, setting out the Board's provisional, non-binding opinion.

VII. The Board's communication was answered by the Respondent.

VIII. Oral proceedings took place on 19 November 1998. Appellant II did not take part in the proceedings (cf. letter dated 9 November 1998). The Respondent submitted a new main request (claims 1 to 40) and one auxiliary request as sole claim requests to be considered by the Board.

The main request differed from the granted claims in that:

- variants: 165-Cys-Asn-Leu; 166-Cys-Asn-Leu, Val 114 and 167-Cys-Asn-Leu, Val 115 were deleted from claims 1 to 3 respectively and,

- claims 5, 11, 12, 18, 29, 30 were deleted and,

- the amino acid sequence of leukocyte interferon B (LeIF B) was attributed to leukocyte interferon C (LeIF C) and the amino acid sequence of LeIF C was attributed to LeIF B.

IX. The following documents on file were considered by the Board:

(1): EP-A-0 032 134

(2): Mantei, N. et al., Gene, vol. 10, 1980, pages 1 to 10,

(4): Nagata, S. et al., Nature, vol. 284, 27 March 1980, pages 316 to 320,

(5): Goeddel, D. et al., Nature, vol. 281, 1979, pages 544 to 548,

(7): DE-A-2 947 134

(9): Streuli, M. et al., Science, vol. 209, 19. September 1980, pages 1343 to 1347,

(10): Nagata, S. et al., Nature, vol. 287, 2 October 1980, pages 401 to 408,

(11): Goeddel, D. et al., Nature, vol. 287, 2 October 1980, pages 411 to 416,

(14): Talmadge, K. et al., Proc.Natl.Acad.Sci. USA vol. 77, No. 7, July 1980, pages 3988 to 3992,

(18): Rubinstein, M., Biochim.Biophys.Acta, vol. 695, 1982, pages 5 to 16.

(19): Allen, G. and K. Fantes, Nature, vol. 287, 2. October 1980, pages 408 to 411,

(20): Petska, S., Scientific American, vol. 249, 1983, pages 37 to 43,

(22): Rubinstein, M. et al., Arch.Biochem.Biophy., vol. 210, No. 1, 1981, pages 307 to 318.

X. The submissions in writing and during oral proceedings by Appellant I can be summarized as follows:

The generic claims to human leukocyte interferons defined by the amino acid sequence Cys-Asn-Leu at the NH2-terminal end (amongst other features) merely enjoyed the third or later priority dates because this amino-acid sequence was disclosed for the first time in the third priority document. For the same reason, the subject-matter of claim 9 which related to the specific mature LeIF-H defined by its sequence only enjoyed the third priority date.

Documents (2) and (4) were the closest prior art to the claims enjoying the first or second priority date. They disclosed the entire cDNA and amino-acid sequence of human leukocyte pre-interferon and its expression from a fused construct in E.coli. The sequence of the mature protein was highlighted in Figure 3 of document (2). In document (4) (passages bridging pages 309 and 310), the presence of the signal sequence was pointed out as the most likely reason for the observed low level of bioactivity. It was also stated therein that an increase in said activity could be achieved by appropriate means, which would necessarily have suggested to the skilled person to express only the part of the cDNA encoding the mature protein.

The problem to be solved was thus to provide further mature interferons and processes for preparing them. Document (5) provided a generally applicable method for manipulating a cloned DNA sequence for direct expression in bacteria. Applying this method to the cDNAs comprising the sequences encoding human mature LeIFs involved no more than routine efforts. The combination of the above documents was thus detrimental to inventive step.

Document (11) published between the second and third priority dates represented the closest prior art to the claims to LeIF-H and to the generic Cys-Asn-Leu LeIFs. It disclosed the expression of mature LeIF-A in E.coli and also that LeIFs existed as a family. A method to construct an expression vector capable of expressing a mature LeIF DNA sequence in E.coli was given in Figure 4. Thus, the skilled person only had to follow the teachings of this document to isolate the claimed generic Cys-Asn-Leu interferons. Furthermore, differences in sequences at the NH2-terminal end would not have been considered unexpected since it was already known from document (2) (page 7) that as many as 9 differences in sequence existed in the first 35 amino acids of LeIF-A and lymphoblastoid interferon. Inventive step was thus lacking from all claims/parts thereof directed to Cys-Asn-Leu interferons. The same was true of claim 9 relating to LeIF-H defined by its entire sequence as it did not exhibit any surprising properties.

XI. The submissions in writing by Appellant II with regard to inventive step were essentially the same as those of Appellant I.

Appellant II also argued that by refusing to consider his submissions under Article 100(b) EPC, the Opposition Division had violated the requirements of Article 114(1) EPC that the EPO shall examine the facts of its own motion.

The requirements of Article 83 EPC were not fulfilled because:

- claim 1 comprised a near infinity of LeIF molecules whereas the patent specification provided no guidance on how to isolate those of them with interferon activity and,

- no teachings were given on how to separate the Met- and des-Met- forms of the LeIF polypeptide.

Furthermore, Appellant II submitted that document (7) anticipated the subject-matter of claim 1, and that the teachings of document (1) (enjoying priority rights from 3 April 1980) as well as those of documents (2) and (4) were detrimental to the novelty of the claim to LeIF-D.

XII. The Respondent argued as follows:

The first priority document of the patent in suit disclosed the essential steps for the production of mature human LeIF-A and -B and the existence of at least six further LeIF DNAs characterized by their restriction maps. It was, thus, fully enabling with regard to making any and all of the claimed interferons. All claims enjoyed the first priority date.

- Document (7) did not disclose a LeIF with the same molecular weight as the now claimed interferons. The other documents cited against novelty either disclosed protein sequences deduced from cDNA sequences or LeIFs with a different amino-acid sequence from those claimed. None could have any bearings on novelty.

- Document (4), which had been published before the first priority date, represented the closest prior art to all claims. It disclosed the expression in E.coli of pre-LeIF from a DNA construct wherein pre-LeIF cDNA was fused to the E.coli beta-lactamase gene. Starting from this prior art, the problem to be solved was to express LeIF in mature form in E.coli. As shown by document (14), the skilled person expected E.coli to be able to cleave off the signal sequence present at the NH2 terminal end of a protein. Thus it would not have been considered necessary to shorten the DNA sequence encoding pre-LeIF DNA to the DNA encoding the mature sequence before insertion into an expression vector. Furthermore, document (5) which allegedly disclosed a general method to tailor DNA sequences for the direct expression of mature proteins in E.coli also disclosed that mature human growth hormone (HGH) expressed in this manner was susceptible to proteolytic degradation. It gave no evidence that E.coli produced mature HGH had biological activity. There was thus no reason to combine the teaching of documents (2) and (4) with that of document (5) to obtain the claimed LeIFs, and no expectation that mature biologically active LeIF could be obtained.

Finally, it ought to be taken into account that in the course of the proceedings the Appellants had proposed two alternative strategies for obtaining the LeIF interferons which the Respondent had been able to prove unworkable. The claimed invention could therefore not have been obvious.

Document (11) was not a document which jeopardized the inventive step of any of the claimed embodiments, quite irrespective of their priority dates, because it did not go beyond the content of the first priority application and it had been published by the inventors themselves. The opinion which the Enlarged Board of Appeal gave on analogous priority issues in the case G 3/93 (OJ EPO 1993, 018), could not be followed because the factual situation underlying that opinion was different.

Nonetheless, inventive step could be acknowledged even if the claims to LeIF-H and to the LeIFs generically defined by the three amino-acids Cys-Asn-Leu were considered to derive their priority from the third or a later priority document and if document (11) was taken as closest prior art. Indeed all LeIFs known at the third priority date (documents (2), (9), (19)) had Cys-Asp-Leu at the NH2 terminal end. This sequence identity at the NH2-terminal end would have been taken as evidence that this portion of the molecule was conserved and, thus, the presence of Asn in position 2 would not have been expected.

- Article 100(b) EPC had not been mentioned as a ground for opposition within the opposition term. The arguments relative thereto should not be allowed into the proceedings.

XIII. The Appellants requested that the decision under appeal be set aside and that the European patent No. 0 211 148 be revoked.

The Respondent requested that the decision under appeal be set aside and the patent be maintained on the basis of the following documents:

(a) claims 1 to 40 submitted during the oral proceedings as main request, or

(b) claims 1 to 38 submitted during oral proceedings as auxiliary request I.

The Respondent further requested to refer the following question to the Enlarged Board of Appeal: "Is the principle of the opinion G 3/93 also applicable if the intervening publication corresponds with regard to the disclosure to the priority document and if the intervening publication is derived from the inventor?"

1. The appeal is admissible.

Articles 114(1) and 100(b) EPC

2. Appellant II objected against the fact that the arguments with regard to Article 100(b) EPC which he submitted one month before the oral proceedings before the Opposition Division had been disregarded for being submitted late. In his view, they ought to have been taken into consideration, although Article 100(b) EPC had not been cited as a ground for opposition in the notice of opposition, in application of Article 114(1) EPC which required that the EPO shall examine the facts of its own motion.

3. In principle, an Opposition Division shall examine only such grounds for opposition which have been properly submitted and substantiated in accordance with Article 99(1) in conjunction with Rule 55(c) EPC (cf. Decision of the Enlarged Board of Appeal G 9/91 (OJ EPO 1993, 408), point 6 of the reasons). Exceptionally, the Opposition Division may in application of Article 114(1) EPC consider other grounds for opposition which, prima facie, in whole or in part would seem to prejudice the maintenance of the European patent (cf. G 9/91, point 16 of the reasons). On the other hand, the possibility of disregarding facts and evidence in support of fresh grounds not submitted in due time under Article 114(2) EPC must also be kept in mind (cf. G 9/91, point 16 of the reasons).

4. In the present case, the Opposition Division was obviously of the opinion that, prima facie, the ground for opposition pursuant to Article 100(b) EPC did not prejudice the maintenance of the patent in suit. Consequently, it refrained from examining that ground. In the Board's judgment, it was within the discretionary power of the Opposition Division to make such a decision. Thus, by refusing to consider the submissions of Appellant II under Article 100(b) EPC, the Opposition Division did not contravene the requirements of Article 114(1) EPC.

5. It is not in conformity with the purpose of the appeal procedure inter partes to consider grounds for opposition on which the decision of the Opposition Division has not been based (cf. G 9/91, point 18 of the reasons). It is therefore justified to apply Article 114(1) EPC generally in a more restrictive manner in such procedure than in opposition procedure (cf. G 9/91, point 18 of the reasons). In particular fresh grounds for opposition may only be introduced at the appeal stage if the patentee agrees that a fresh ground for opposition may be considered (cf. G 9/91, point 18 of the reasons).

6. In the present case, given the facts that:

(i) the ground for opposition pursuant to Article 100(b) EPC was not properly submitted and substantiated in accordance with Article 99(1) in conjunction with Rule 55(c) EPC, and

(ii) Article 114(1) EPC is to be applied in a more restrictive manner in the appeal procedure inter partes than in opposition procedure (cf. point 5, above), and

(iii) the submissions of Appellant II under Article 100(b) EPC are, in the Board's judgment, not of prima facie relevance, and

(iv) the Respondent already argued in opposition proceedings before the first instance that the argumentation pursuant to Article 100(b) EPC should be considered inadmissible (letter dated 25. November 1994),

the issue of whether or not the patent in suit and the invention to which it relates meet the requirement of Article 83 EPC will not be examined.

Main request

Articles 123(2)(3) EPC

7. All of the interferons, DNA/plasmid/bacterial hosts encoding/expressing them and processes which are claimed have been disclosed in the application as filed. The requirements of Article 123(2)EPC are fulfilled.

8. Claims 1 to 3 of the main request comprise a smaller number of alternative interferons than claims 1 to 3 as granted. Granted claims 5, 11, 12, 18, 29 and 30 have been deleted. None of these amendments results in an extension in the protection conferred by the granted claims. The requirements of Article 123(2) EPC are fulfilled.

9. The sequence of LeIFB (claim 5) corresponds to the sequence of LeIFC claimed in claim 7 of the granted claim request. The sequence of LeIFC (claim 6) corresponds to the sequence of LeIFB claimed in claim 6 of the granted claim request. The Respondent argued that the sequences of LeIFB and LeIFC had mistakenly been exchanged in the granted claims, and that therefore, a correction was allowable under Rule 88 EPC.

10. In accordance with the case law of the EPO (cf. G 3/89, OJ EPO 1993, 117), the correction of obvious errors is only allowable if it can objectively be derived from the description, claims and drawings of the European patent application as filed, and if it is immediately evident that nothing else would have been intended than what is offered as the correction.

11. The application as filed discloses the protein sequences of LeIFB and LeIFC in Figure 4. They are identical to the sequences of LeIFB and LeIFC in claims 5 and 6 of the main request. Furthermore, the DNA sequences encoding LeIFB and LeIFC are given in Figure 3. They are such that the LeIFB DNA can only encode the protein sequence shown in Figure 4 as that of LeIFB and that the LeIFC DNA can only encode the protein sequence shown in Figure 4 as that of the LeIFC interferon. Accordingly, it is immediately obvious that no other sequence could have been intended for LeIFB than that disclosed in the application as filed and claimed in claim 5 of the main request and that no other sequence could have been intended for LeIFC than that disclosed in the application as filed and claimed in claim 6 of the main request. The correction under Rule 88 EPC is allowable.

12. The same two molecules are claimed in claims 5 and 6 of the main request as in claims 6 and 7 of the granted set of claims (albeit under a different denomination). The protection conferred is not extended.

13. The requirements of Article 123(3) EPC are fulfilled.

Priority: Articles 87 and 88 EPC

14. The claimed generic molecules can be regrouped in two clusters, depending on the amino-acid sequence at their NH2-terminal end being either Cys-Asp-Leu or Cys-Asn-Leu. The specific LeIF-B to D and LeIF-F molecules (claims 5 to 8) belong to the first cluster whereas LeIF-H (claim 9) belongs to the second one.

15. The first and second priority documents disclose the first cluster of molecules as well as methods of general applicability for the isolation of cDNAs encoding LeIFs and for their insertion into an expression vector in such a manner that the DNA sequence encoding mature LeIF is expressed in unfused form. By applying these methods, it is in principle possible to obtain any LeIF, quite irrespective of its amino-acid sequence.

16. The second cluster of LeIFs and LeIF-H are described for the first time in the third priority document. The specific amino acid sequence Cys-Asn-Leu at the NH2- terminal end is the feature which distinguishes these LeIFs from all other known interferons. It is thus an essential characterising feature of the cluster, which could have been derived neither explicitly nor implicitly from the teachings of the first two priority documents.

17. The dependent claims cover subject-matter disclosed in the same priority documents as the independent claims/parts thereof they depend upon.

18. Accordingly, in line with established case law (cf. e.g. T 81/87, OJ EPO 1990, 250), claim 9 and claims 1 to 4, insofar as they relate to Cys-Asn-Leu LeIFs (and dependent claims thereof) are not entitled to the first or the second priority date, but only to the third or later priority dates depending on which of these priority documents discloses the specific sequences (including Cys-Asn-Leu) characterising them.

Article 54 EPC

19. Document (7) was argued to be detrimental to the novelty of claim 1 relating to LeIF-166-Cys-Asp-Leu belonging to the first cluster, provided that its teachings were corrected with those of the post-published document (18). Documents (2) and (4) were argued to be detrimental to the novelty of the claim to LeIF-D also belonging to the first cluster of interferon molecules.

20. Document (7) discloses the molecule IFN- 2 isolated from natural sources and characterized by a molecular weight of 17500 daltons (determined, according to document (22), with cytochrome C and chymotrypsinogen A as molecular weight standards), and by the fact that it is composed of 152 amino-acids. In document (18), the molecular weight of IFN- 2 was experimentally determined as being 19500 daltons (using a different set of molecular weight markers from that of document (7)) and the number of amino-acids in the molecule was experimentally found to be 164.

21. The molecular weight of LeIF-D can be approximately calculated as 19500 daltons and the molecule comprises 166 amino acids.

22. There is no evidence on file as to which molecular weight markers will provide the experimentally determined molecular weight closest to the approximately calculated one. Furthermore, it is not readily apparent why the number of amino acids experimentally determined in document (18) should be more accurate than the number of amino-acids experimentally determined in document (7). In the Board's judgment, the available data do not provide an unambiguous characterization of IFN- 2. In addition, the experimentally determined number of amino-acids is different in both documents from the claimed number of amino-acids (165 or 166). Accordingly, the Board does not consider document (7) as detrimental to novelty.

23. Document (2) discloses cDNAs encoding leukocyte pre-interferons and the protein sequences deduced therefrom. Document (4) discloses the expression in E.coli of the pre-LeIF of document (2) from a fused construct. As for document (1), the part of this document which enjoys the priority of 3 April 1980 corresponds to Documents (2) and (4). None of these documents discloses the DNA encoding the mature form of LeIF or the LeIF mature protein. Accordingly, they cannot be detrimental to novelty.

24. No other documents on file disclose subject-matter which could destroy novelty. The requirements of Article 54 EPC are fulfilled.

Inventive step

Claims enjoying the first or second priority date

25. The closest prior art is represented by document (4) published on 27 March 1980. This describes an experiment aimed at expressing in E.coli a DNA construct comprising part of the E.coli beta-lactamase gene and, attached to it, a DNA fragment comprising the pre-leukocyte interferon coding sequence. The protein expressed from this hybrid construct is shown to have LeIF biological activity. Its molecular weight does not correspond to that expected for the fused protein. It is rather consistent with that of a polypeptide, the translation of which was initiated at the physiological initiation site of the pre-LeIF sequence. The authors discuss the possibilities that the observed biological activity is due to pre-LeIF and that the low level of synthesis observed might be caused by the rare occurrence of the internal translational event. They suggest that this problem could be alleviated by modifying the structure of the hybrid plasmid.

26. Starting from the closest prior art, the objective technical problem to be solved is the production of mature members of the LeIF family in E.coli.

27. The solution provided is to clone the cDNAs encoding the pre-LeIFs, to shorten their sequences to those sequences encoding the mature LeIFs and to insert the DNA fragments thus obtained into a vector for direct expression in E.coli.

28. The Board is satisfied that mature LeIFs have been obtained as disclosed in the patent in suit.

29. Appellant I argued that document (4) itself suggested to insert the DNA sequences encoding the mature LeIFs into an expression vector. In the Board's judgment, however, no such suggestion is made. The authors of document (4) discuss appropriate modifications of the hybrid plasmid, they had constructed, in connection with eliminating the problem associated with internal translation initiation. This problem is not connected with making mature LeIFs rather than pre-LeIFs.

30. Failing to find any suggestion in document (4) on how to produce mature LeIFs in E.coli, the skilled person may have turned to the general state of the art for guidance. The evidence on file shows that in the mid- 80s, the art of expressing in E.coli eukaryotic proteins in their natural, biologically active forms was very much in its infancy. In fact, the only document published before the first or second priority date which is cited in this context is document (5). According to its authors, the then conventional expression methods utilised either chemically synthesized DNA or cDNA exclusively, the cDNA approach being used to express fusion proteins (passage bridging column 1 and 2, page 544). Document (5) discloses a method for the expression of mature human growth hormone in E.coli which involves shortening the cDNA to the DNA fragment consisting of the "mature coding sequence" and inserting this fragment into an expression vector. The presence of human growth hormone in the bacterial extracts is shown by radioimmunoassay. The biological activity of the protein is not tested. Evidence is presented for some proteolytic degradation taking place.

31. It is possible that the skilled person may have thought of combining the teaching of document (4) (cloning of LeIF cDNAs) with the teaching of document (5) (insertion of the "mature coding sequence" in the expression vector), to produce mature LeIFs in E.coli. Yet, in the Board's judgment, this combination would not have been regarded as having a reasonable expectation of success, as document (5) appears to have been the only state of the art pointing in this direction and did not provide such conclusive results neither with regard to the possibility of producing the mature protein in stable form, nor with regard to its properties.

32. Document (14) published between the first and second priority date advises that bacteria are capable of cleaving eukaryotic signals (page 3991). If anything, it teaches away from the present invention, as it precludes the necessity of using DNA sequences encoding the mature protein to produce said protein in a foreign host. There are no other documents on file, the combination of which with document (4) would be detrimental to inventive step.

33. Accordingly, inventive step is acknowledged in respect of the subject-matter of the claims enjoying the first or second priority date.

Claim 9 and claims to LeIF characterized by the sequence Cys-Asn-Leu at the NH2-terminal end

34. Claim 9 enjoys the third priority date. Claims relating to generic Cys-Asn-Leu LeIFs similarly enjoy the third or a later priority date depending on which of these priority documents disclose the specific features (including Cys-Asn-Leu) characterising them (see points 14 to 16 above).

35. The closest prior art is represented by document (11) published on 2 October 1980. This document discloses the direct expression in E.coli of mature leukocyte interferon LeIF-A characterized by the sequence Cys-Asp-Leu at the NH2-terminal end . It teaches that there exists a family of LeIFs (page 411). The method used to obtain the expression of mature LeIF-A is said to be generally applicable (page 415).

36. Starting from this prior art, the objective technical problem to be solved can be defined as the provision of another member of the LeIF family. The formulation of this problem is not in itself inventive since the existence of the LeIF family was known.

37. The solution is the claimed LeIFs characterized in particular by the sequence Cys-Asn-Leu at the NH2-terminal end.

38. The state of the art at the third priority date discloses four other interferons in addition to LeIF-A: LeIF-I (document (2)), LE-IF 2 (document(9)), IF A and IF B from Namalva cells (document (19)). The five interferons have the following amino-acid sequence at the NH2 terminal end: Cys-Asp-Leu-Pro- (Glu or Gln) - Thr-His-Ser-Leu- (Asp or Gly) -... In the Board's judgment, these data would be interpreted by the skilled person as meaning that the NH2-terminal end is relatively well conserved (80%) and that the amino-acids in positions 5 and 10 are the ones which can vary without altering the biological properties of the molecule. Otherwise stated, starting from the available prior art, the skilled person would not have expected that a member of the interferons family could differ from the other members of the family in position 2. This unexpected result justifies recognition of inventive step for the subject-matter of the claims enjoying the third priority date.

39. Post-published document (20) shows that LeIF-H is the only interferon out of eleven members of the IFN family to carry Cys-Asn-Leu at the NH2-terminal end. Thus, this last feature remained unexpected even after the filing date of the patent in suit. Accordingly, all claims to LeIFs characterized by the sequence Cys-Asn-Leu are considered inventive irrespective of their priority date being the third or a later priority date.

40. The requirements of Article 56 EPC are fulfilled by the subject-matter of all claims.

Question to the Enlarged Board of Appeal

41. This question (cf. point XIII, above) was submitted by the Respondent in the context of determining whether document (11) is a prior art document to be taken into account when assessing the inventive step of the subject-matter of the claims enjoying the third or a later priority date. In the course of the proceedings, it was established that the subject-matter of these claims involves an inventive step, even if document (11) is considered the closest prior art (cf. points 34 to 39, above). The question, thus, need not be addressed. No decision within the meaning of Article 112(1)(a) EPC is required. Consequently, the Respondent's request is refused (Article 112(1)(a), last sentence EPC).

Order

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the first instance with the order to maintain the patent on the basis of claims 1 to 40 submitted during oral proceedings as main request, and the description, pages 3, 5, 6, 17, 18, 20 submitted during oral proceedings and pages 4, 7 to 16, 19. as granted, and drawings, Figure 4 submitted during oral proceedings and Figures 1 to 3, 5 to 9 as granted.

3. The request to refer a question to the Enlarged Board of Appeal is refused.

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility